<br>针对结肠炎症治疗炎症性肠病的口服纳米药物系统：最新进展,Journal of Materials Chemistry B

当前位置： X-MOL 学术 › J. Mater. Chem. B › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

针对结肠炎症治疗炎症性肠病的口服纳米药物系统：最新进展
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2023-11-29 , DOI: 10.1039/d3tb02302h
Shumeng Hu _{1,

2} , Runan Zhao _{2,

3} , Yu Xu _{2,

4} , Zelin Gu ₁ , Beiwei Zhu _{1,

2,

4} , Jiangning Hu _{2,

4}

Affiliation

炎症性肠病 (IBD) 是一种慢性特发性疾病，会导致胃肠道炎症，从而导致溃疡性结肠炎和克罗恩病等疾病。 IBD 常用的治疗方法包括抗炎药、免疫抑制剂和抗生素。粪便微生物群移植也正在探索作为一种潜在的治疗方法；然而，这些药物可能会导致全身副作用。 IBD 治疗首选口服给药，但由于多重生理障碍，准确定位结肠发炎区域具有挑战性。纳米颗粒药物输送系统具有独特的理化特性，能够利用发炎肠道增加的渗透性和滞留效应，将药物精确输送到 IBD 治疗的目标部位。本文第一部分全面介绍了IBD的病理生理环境，包括胃肠道pH值、途径中的各种酶、转运时间、肠道粘液、肠上皮、肠道免疫细胞和肠道微生物群。第二部分重点介绍结肠炎相关领域口服纳米颗粒药物递送系统靶向递送机制和策略的最新进展。最后，我们提出了未来借助纳米技术治疗 IBD 的挑战和潜在方向。

"点击查看英文标题和摘要"

Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances

Inflammatory bowel disease (IBD) is a chronic and idiopathic condition that results in inflammation of the gastrointestinal tract, leading to conditions such as ulcerative colitis and Crohn's disease. Commonly used treatments for IBD include anti-inflammatory drugs, immunosuppressants, and antibiotics. Fecal microbiota transplantation is also being explored as a potential treatment method; however, these drugs may lead to systemic side effects. Oral administration is preferred for IBD treatment, but accurately locating the inflamed area in the colon is challenging due to multiple physiological barriers. Nanoparticle drug delivery systems possess unique physicochemical properties that enable precise delivery to the target site for IBD treatment, exploiting the increased permeability and retention effect of inflamed intestines. The first part of this review comprehensively introduces the pathophysiological environment of IBD, covering the gastrointestinal pH, various enzymes in the pathway, transport time, intestinal mucus, intestinal epithelium, intestinal immune cells, and intestinal microbiota. The second part focuses on the latest advances in the mechanism and strategies of targeted delivery using oral nanoparticle drug delivery systems for colitis-related fields. Finally, we present challenges and potential directions for future IBD treatment with the assistance of nanotechnology.

更新日期：2023-11-29

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南